ASCO 2020 | Reflections on the ADAURA study

Jared Weiss, MD, of UNC Lineberger, Chapel Hill, NC, discusses highlights on non-small cell lung cancer (NSCLC) presented at ASCO 2020. Dr Weiss reflects on data from the ADAURA study (NCT02511106) in which patients with stage IB–IIIA EGFR mutation positive NSCLC patients were treated with osimertinib as adjuvant therapy after complete tumor resection. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).